Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology
Mark Selby(Bristol-Myers Squibb (Germany)), Alan J. Korman(Bristol-Myers Squibb (Germany))
Cited by 228
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy
|Cell Reports|2019|297
A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target
|Journal of Clinical Investigation|2020|133